D. Boral Capital Reaffirms Buy Rating for Medicus Pharma (NASDAQ:MDCX)

Medicus Pharma (NASDAQ:MDCX)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $27.00 price target on the stock.

Several other research firms also recently commented on MDCX. Maxim Group upped their price objective on Medicus Pharma from $10.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Wall Street Zen raised Medicus Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 30th. Finally, D Boral Capital raised shares of Medicus Pharma to a “strong-buy” rating in a research note on Monday, April 14th. One research analyst has rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Medicus Pharma has a consensus rating of “Buy” and a consensus target price of $23.50.

Medicus Pharma Trading Up 2.4%

Shares of NASDAQ MDCX opened at $2.95 on Monday. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $8.94. The stock has a 50 day moving average of $4.40 and a two-hundred day moving average of $3.51.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.19). On average, equities research analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Medicus Pharma

In related news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of Medicus Pharma stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $7.72, for a total transaction of $579,000.00. Following the completion of the transaction, the insider now directly owns 3,248,741 shares of the company’s stock, valued at approximately $25,080,280.52. The trade was a 2.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Hedge Funds Weigh In On Medicus Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Interchange Capital Partners LLC purchased a new stake in shares of Medicus Pharma in the fourth quarter valued at $3,628,000. Armistice Capital LLC acquired a new position in shares of Medicus Pharma in the 1st quarter valued at about $4,710,000. Finally, Private Advisor Group LLC purchased a new stake in Medicus Pharma during the first quarter worth approximately $211,000.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.